Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBAI20 hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- CyTuVax
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HBAI20 is an investigational hepatitis B vaccine developed by CyTuVax BV, specifically designed for individuals who fail to achieve protective antibody levels after standard vaccination (non-responders). It is a combination product consisting of the licensed recombinant hepatitis B vaccine HBVaxPro (containing 10 µg of HBsAg) and a proprietary adjuvant called AI20. The AI20 adjuvant is composed of 20 µg of recombinant human interleukin-2 (IL-2) aggregates adsorbed to 20 µg of aluminium hydroxide. This formulation acts as a depot at the injection site, allowing for the slow release of highly concentrated IL-2 aggregates, which enhances the immune response to the hepatitis B surface antigen. HBAI20 has completed Phase 2 clinical testing (the BE-Responder trial), demonstrating significantly improved seroconversion rates in previous non-responders compared to standard vaccination.
- Other names
- HBAI20HBAI-20HBAI 20
02
Targets
HBsAg (Hepatitis B surface antigen)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on HBAI20 hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBAI20 hepatitis B vaccine.